Ocumetics' breakthrough lens restores vision for legally blind patients in landmark trial

Ocumetics has announced strong results from the first group of patients in its clinical trial for an advanced accommodating intraocular lens. The study showed major improvements in vision, even for those with severe preoperative blindness. Company leaders now describe the technology as a potential breakthrough in eye care.

Group 1 participants included patients with vision as poor as 20/250 before surgery—levels consistent with legal blindness. After receiving the Ocumetics Lens, their sight improved dramatically, surpassing expectations for visual sharpness. The device also met all safety benchmarks, with no complications reported in lens delivery or postoperative recovery.

Dr. Rafael Vázquez, the study's principal investigator, confirmed that every patient achieved outcomes that exceeded safety targets. The real-world impact was described as life-changing for those who had struggled with severe visual impairment. Dean Burns, CEO of Ocumetics, called the results a validation of the lens technology and its ability to restore functional vision.

The company has now begun manufacturing and testing refined lens designs for Group 2 surgeries. A fast-paced research approach, dubbed 'win-learn,' will guide further optimisation before the next phase. Burns will also host a webinar to present the three-month findings and updates on the first-in-human (FIH) study.

The Group 1 trial cleared all internal performance and safety goals, allowing Ocumetics to move forward with expanded testing. Optimised lenses are already in production, with Group 2 surgeries planned in the near future. The results suggest the technology could offer a reliable solution for patients with advanced vision loss.